iGlarLixi versus Basal Plus Rapid-Acting Insulin in Adults with Type 2 Diabetes Advancing from Basal Insulin Therapy: The SoliSimplify Real-World Study

Rory McCrimmon (Lead / Corresponding author), Alice Y. Y. Cheng, Gagik R. Galstyan, Khier Djaballah, Xuan Li, Mathieu Coudert, Juan P. Frias

    Research output: Contribution to journalArticlepeer-review

    5 Citations (Scopus)
    106 Downloads (Pure)

    Abstract

    Aim: For people with suboptimally controlled type 2 diabetes (T2D) on basal insulin (BI), guidelines recommend several treatment advancement options. This study compared the clinical effectiveness of once-daily iGlarLixi versus a multiple-injection BI + rapid acting insulin (RAI) regimen in adults with T2D advancing from BI therapy in real-world clinical practice.

    Materials and methods: Electronic medical records from the Observational Medical Outcomes Partnership (OMOP) database were analysed retrospectively using propensity score matching to compare therapy advancement with iGlarLixi or BI + RAI in US adults ≥18 years with T2D on BI who had ≥1 valid glycated haemoglobin (HbA1c) value at baseline and at the 6-month follow-up. The primary objective was non-inferiority of iGlarLixi to BI + RAI in HbA1c change from baseline to 6 months (margin 0.3%).

    Results: Propensity score matching generated cohorts with balanced baseline characteristics (N = 814 in each group). HbA1c reduction from baseline to 6 months with iGlarLixi was non-inferior to BI + RAI [mean difference (95% confidence interval): 0.1 (−0.1, 0.2)%; one-sided p =.0032]. At 6 months, weight gain was significantly lower with iGlarLixi than with BI + RAI [−0.8 (−1.3, −0.2) kg; two-sided p =.0069]. Achievement of HbA1c <7% without hypoglycaemia and weight gain were similar between groups [odds ratio (95% confidence interval): 1.15 (0.81, 1.63); p =.4280]. Hypoglycaemia was low in both groups, probably because of underreporting.

    Conclusions: In real-world clinical practice, glycaemic outcomes 6 months after treatment advancement from BI are similar for people with T2D using iGlarLixi versus BI + RAI, with iGlarLixi leading to less weight gain.

    Original languageEnglish
    Pages (from-to)68-77
    Number of pages10
    JournalDiabetes, Obesity & Metabolism
    Volume25
    Issue number1
    Early online date19 Aug 2022
    DOIs
    Publication statusPublished - Jan 2023

    Keywords

    • basal insulin
    • database research
    • GLP-1 analogue
    • glycaemic control
    • iGlarLixi
    • type 2 diabetes
    • glucagon-like peptide-1 analogue

    ASJC Scopus subject areas

    • Endocrinology
    • Internal Medicine
    • Endocrinology, Diabetes and Metabolism

    Fingerprint

    Dive into the research topics of 'iGlarLixi versus Basal Plus Rapid-Acting Insulin in Adults with Type 2 Diabetes Advancing from Basal Insulin Therapy: The SoliSimplify Real-World Study'. Together they form a unique fingerprint.

    Cite this